At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
BG-60366 is designed to break down the mutated EGFR protein, which promotes the growth of NSCLC. BG-60366 is taken orally (by mouth).
-
Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient's white blood cells.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
-
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
-
The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).
-
Researchers want to see if adding autogene cevumeran to nivolumab is better than nivolumab alone to treat urothelial (bladder) cancer. The people in this study have muscle-invasive urothelial cancer (MIUC) that has been removed with surgery.
- A Phase II Study of MB-CART2019.1 CAR T-Cell Therapy in People with Diffuse Large B-Cell Lymphoma
Full Title A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Purpose
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient’s own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
In this study, researchers are evaluating a new type of CAR T-cell therapy called MB-CART2019.1 in people with diffuse large B-cell lymphoma (DLBCL) that continues to grow despite prior treatment. MB-CART2019.1 is designed to target two proteins (CD19 and CD20) on DLBCL cells. This targeting action may help MB-CART2019.1 find cancer cells and kill them.
Participants in this study will receive fludarabine and cyclophosphamide chemotherapy before MB-CART2019.1. This prepares the body for treatment and helps MB-CART2019.1 work better to fight cancer. The treatments in this study are all given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have DLBCL that has come back or continued to grow despite at least two prior regimens of treatment that included rituximab and anthracycline.
- Patients must have either experienced return of their disease after autologous stem cell transplant (ASCT) or were not eligible for or consented to ASCT.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Miguel-Angel Perales at 646-608-3757.
Protocol
21-307Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04792489ClinicalTrials.gov
-
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.